Payment overview · 2025
General Payments
$544.12
19 reported records · 11 companies
Healthcare provider profile · identity verified
Gust Pantelas, MD
Allopathic & Osteopathic Physicians|Family Medicine · NORTH CANTON, OH · NPI 1184689432
Verified facts
What the public records show
CMS Open Payments records show Gust Pantelas, MD received $544.12 in general payments during 2025 across 19 reported records.
Inspire Medical Systems, Inc. accounted for 28.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $152.92 | 28.1% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $145.45 | 26.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $69.52 | 12.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.89 | 9.7% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $22.35 | 4.1% | 1 | 2025 |
| Krystal Biotech Inc | Unresolved — no canonical attribution shown | $20.62 | 3.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.89 | 3.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.62 | 3.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.97 | 2.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.05 | 2.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.84 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $544.12 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $152.92 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $69.52 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $51.46 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $30.37 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| VYJUVEK Normalized: vyjuvek |
Drug | Krystal Biotech Inc | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 126 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
126 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
126 | 33 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 473 | 127 |
| Amlodipine Besylate | Amlodipine Besylate | 358 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 348 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 314 | 89 |
| Losartan Potassium | Losartan Potassium | 287 | 79 |
| Lisinopril | Lisinopril | 279 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 277 | 80 |
| Omeprazole | Omeprazole | 239 | 70 |
| Simvastatin | Simvastatin | 237 | 65 |
| Ezetimibe | Ezetimibe | 174 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 132 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 41 |
| Eliquis | Apixaban | 126 | 33 |
| Metformin Hcl | Metformin Hcl | 114 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 33 |
| Jardiance | Empagliflozin | 109 | 31 |
| Furosemide | Furosemide | 105 | 34 |
| Tramadol Hcl | Tramadol Hcl | 103 | 22 |
| Potassium Chloride | Potassium Chloride | 99 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 94 | 26 |
| Sertraline Hcl | Sertraline Hcl | 87 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 24 |
| Glimepiride | Glimepiride | 78 | 21 |
| Lorazepam | Lorazepam | 69 | 19 |
| Metformin Hcl Er | Metformin Hcl | 68 | 20 |
| Trazodone Hcl | Trazodone Hcl | 68 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 59 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 14 |
| Xarelto | Rivaroxaban | 51 | 14 |
| Finasteride | Finasteride | 49 | 17 |
| Alprazolam | Alprazolam | 47 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 47 | 14 |
| Allopurinol | Allopurinol | 44 | 13 |
| Carvedilol | Carvedilol | 43 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 13 |
| Gabapentin | Gabapentin | 40 | 13 |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Lansoprazole | Lansoprazole | 34 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 12 |
| Irbesartan | Irbesartan | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | 12 |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Meloxicam | Meloxicam | 28 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Prednisone | Prednisone | 25 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 23 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 18 |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Tenormin | Atenolol | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $544.12 · 19 records | Inspire Medical Systems, Inc. | Auvelity, CAMZYOS, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, GARDASIL 9, GEMTESA, INSPIRE, NURTEC ODT, Ozempic, ROTATEQ, VAXELIS, VAXNEUVANCE, VOQUEZNA, VRAYLAR, VYJUVEK, Wegovy, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error